A comparison of thrombotic thrombocytopenic purpura in an inception cohort of patients with and without systemic lupus erythematosus
Open Access
- 30 January 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 48 (4) , 399-403
Abstract
Objectives. To compare the clinical presentation, response to therapy and outcome of thrombotic thrombocytopenic purpura (TTP) in an inception cohort of patients with and without SLE. Methods. Medical records of patients diagnosed with TTP at Singapore General Hospital between January 2003 and December 2007 were reviewed. Results. Ten idiopathic TTP (iTTP) and eight SLE-associated TTP (sTTP) patients were identified, with iTTP patients being older (mean 50.4 vs 34.5 yrs). Five iTTP patients were ANA positive but did not have any features of SLE. All sTTP patients had active SLE at TTP diagnosis and had more renal involvement than iTTP (87.5% vs 50%). The mean duration from the first symptom suggestive of TTP to diagnosis was 7.7 days and 19.5 days in iTTP and sTTP patients. All patients received high-dose corticosteroids. Cytotoxic and immunosuppressive drugs were used more commonly (87.5% vs 50%) and earlier (Day 2/3 vs after Day 7) in sTTP patients. Vincristine was the drug of choice in iTTP and cyclophosphamide in sTTP. Three SLE patients received rituximab. Mortality for iTTP and sTTP was 50% (95% CI 19%, 81%) and 62.5% (95% CI 29%, 96%), respectively. The mean (s.d.) time to complete remission was 31.3 (± 26.4) days in sTTP (n = 3) and 16.8 (± 6.1) days in iTTP (n = 5). Conclusion. Despite early and more aggressive therapy in sTTP, mortality was higher and the time to complete remission were longer, suggesting that sTTP is more severe. The tempo of development of TTP in SLE patients was slower.Keywords
This publication has 28 references indexed in Scilit:
- Rituximab in recalcitrant thrombotic thrombocytopenic purpura secondary to systemic lupus erythematosusInternational Journal of Rheumatic Diseases, 2008
- Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS‐13British Journal of Haematology, 2006
- Rituximab therapy for thrombotic thrombocytopenic purpura: A proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune‐mediated disordersJournal of Clinical Apheresis, 2006
- Thrombotic Thrombocytopenic Purpura Associated with Systemic Lupus ErythematosusActa Haematologica, 2006
- The incidence of thrombotic thrombocytopenic purpura‐hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS‐13 deficiencyJournal of Thrombosis and Haemostasis, 2005
- Systemic lupus erythematosus and thrombotic thrombocytopenic purpura: a case report and literature reviewClinical Rheumatology, 2003
- Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosusArthritis & Rheumatism, 1997
- Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a multivariate analysis of factors predicting the response to plasma exchangeAnnals of Hematology, 1995
- Clinical and neuropathological findings in systemic lupus erythematosus: The role of vasculitis, heart emboli, and thrombotic thrombocytopenic purpuraAnnals of Neurology, 1988
- HUS and TTP: Variable expression of a single entityKidney International, 1987